End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,680 KRW | +0.75% | +0.56% | -12.85% |
2023 | PeopleBio, Inc. announced that it has received KRW 5.399992647 billion in funding | CI |
2023 | Peoplebio to Raise 5.4 Billion Won From Shares Issuance | MT |
Business Summary
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Food Material Development, Chemical Substance Development, Supply and Consulting Product
90.6
%
| - | - | 4,032 | 90.6 % | - |
Food Material Development, Chemical Substance Development, Supply and Consulting Merchandise
9.4
%
| - | - | 421 | 9.4 % | - |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
99.5
%
| 4,416 | 99.3 % | 4,432 | 99.5 % | +0.37% |
Asia
0.4
%
| 29 | 0.7 % | 18 | 0.4 % | -37.03% |
Europe
0.1
%
| - | - | 2 | 0.1 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sung-Min Kang
FOU | Founder | 52 | 02-09-08 |
Dae-Won Cho
DFI | Director of Finance/CFO | 51 | 02-09-08 |
Sang-Chul Ahn
AUD | Comptroller/Controller/Auditor | 51 | 18-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Sung-Min Kang
FOU | Founder | 52 | 02-09-08 |
Sung-Yoon Hwang
BRD | Director/Board Member | 63 | 18-11-30 |
Dae-Won Cho
DFI | Director of Finance/CFO | 51 | 02-09-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 21,147,310 | 17,078,484 ( 80.76 %) | 57,846 ( 0.2735 %) | 80.76 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
PEOPLEBIO, INC. 0.24% | 50,000 | 0.24% | 97,497 $ |
Company contact information
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-12.85% | 41.65M | |
-4.67% | 12.32B | |
-5.19% | 8.07B | |
+9.45% | 5.92B | |
+28.50% | 5.52B | |
-8.09% | 4.21B | |
-55.31% | 2.99B | |
+13.49% | 2.73B | |
-1.34% | 2.43B | |
+32.24% | 2.29B |
- Stock Market
- Equities
- A304840 Stock
- Company PeopleBio, Inc.